Literature DB >> 1416886

Adaptive resistance following single doses of gentamicin in a dynamic in vitro model.

M L Barclay1, E J Begg, S T Chambers.   

Abstract

Adaptive resistance is a phenomenon recently described for Pseudomonas aeruginosa and other gram-negative bacilli following exposure to aminoglycoside antibiotics. It is a reversible form of resistance which develops within 1 to 2 h of initial exposure to an aminoglycoside and disappears several hours after removal of the antibiotic. We investigated adaptive resistance in P. aeruginosa ATCC 27853 following single doses of gentamicin by using a dynamic in vitro model which mimics in vivo pharmacokinetics. The initial peak gentamicin concentrations were 2.5, 8, and 25 mg/liter, and these were followed by an exponential decay in the concentration, with a half-life of 2.5 h. The degree of adaptive resistance was greater and the duration was longer with higher initial gentamicin concentrations. Maximal adaptive resistance occurred between 2 and 10 h following 8 mg/liter and between 2 and 16 h following 25 mg/liter. Full recovery of susceptibility occurred at approximately 36, 39, and 43 h following 2.5, 8, and 25 mg/liter, respectively, at which times the gentamicin concentrations were extremely low. Longer dosing intervals for aminoglycosides may improve efficacy by allowing time for adaptive resistance to resolve.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416886      PMCID: PMC192214          DOI: 10.1128/AAC.36.9.1951

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  Two forms of antimicrobial resistance: bacterial persistence and positive function resistance.

Authors:  L E Bryan
Journal:  J Antimicrob Chemother       Date:  1989-06       Impact factor: 5.790

2.  Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.

Authors:  E W ter Braak; P J de Vries; K P Bouter; S G van der Vegt; G C Dorrestein; J W Nortier; A van Dijk; R P Verkooyen; H A Verbrugh
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

3.  Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation.

Authors:  G L Daikos; G G Jackson; V T Lolans; D M Livermore
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

4.  Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis.

Authors:  S T Fan; W Y Lau; C H Teoh-Chan; K F Lau; E H Mauracher
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790

5.  Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection.

Authors:  P Van der Auwera; F Meunier; S Ibrahim; L Kaufman; M P Derde; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

6.  [The single daily dose of gentamicin in the treatment of urinary tract infections (author's transl)].

Authors:  A Angelov; G Barrientos; G Gutensohn; A Lenzner
Journal:  MMW Munch Med Wochenschr       Date:  1980-02-08

7.  Antimicrobial effects of lomefloxacin in vitro.

Authors:  S T Chambers; B A Peddie; R A Robson; E J Begg; D R Boswell
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

8.  Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa.

Authors:  L B Gilleland; H E Gilleland; J A Gibson; F R Champlin
Journal:  J Med Microbiol       Date:  1989-05       Impact factor: 2.472

Review 9.  Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity.

Authors:  G L Chan
Journal:  DICP       Date:  1989-10

10.  Tolerance of once-daily dosing of netilmicin and teicoplanin, alone or in combination, in healthy volunteers.

Authors:  C Pierre; F Blanchet; N Seta; P Chaigne; C Labarre; O Sterkers; C Amiel; C Carbon
Journal:  Clin Pharmacol Ther       Date:  1988-10       Impact factor: 6.875

View more
  35 in total

Review 1.  Aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

2.  Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations.

Authors:  C Wiuff; R M Zappala; R R Regoes; K N Garner; F Baquero; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 3.  Regulation of antimicrobial resistance by extracytoplasmic function (ECF) sigma factors.

Authors:  Emily C Woods; Shonna M McBride
Journal:  Microbes Infect       Date:  2017-01-30       Impact factor: 2.700

Review 4.  Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal.

Authors:  J C Hurley
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

5.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

Review 6.  Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?

Authors:  M L Barclay; C M Kirkpatrick; E J Begg
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

7.  Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.

Authors:  Ami F Mohamed; Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

8.  Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Authors:  Vanessa E Rees; Jürgen B Bulitta; Antonio Oliver; Brian T Tsuji; Craig R Rayner; Roger L Nation; Cornelia B Landersdorfer
Journal:  J Antimicrob Chemother       Date:  2016-08-11       Impact factor: 5.790

9.  Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro.

Authors:  M L Barclay; E J Begg; S T Chambers; D R Boswell
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

10.  Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.

Authors:  B J McGrath; K C Lamp; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.